Introduction
============

Radiation-induced sarcoma (RIS) is a rare late event after radiation therapy (RT), with a reported incidence of 0.03%- 0.2% in 5 years and overall up to 0.8% \[[@b1-crt-2015-171],[@b2-crt-2015-171]\]. It is known to have a worse prognosis than sporadic soft tissue sarcoma (STS), with a 5-year disease-specific survival (DSS) rate of 32%-58% in recent reports \[[@b3-crt-2015-171]-[@b5-crt-2015-171]\]. Gladdy et al. \[[@b3-crt-2015-171]\] reported that RIS had a worse DSS than sporadic STS with a hazard ratio of 1.7. Dineen et al. \[[@b6-crt-2015-171]\] also recently reported a lower DSS of RIS than of sporadic STS.

Because RIS arises in the previously treated area, there are many limitations in its management. The major limitation is that RIS has lower resectability than sporadic sarcomas. Thijssens et al. \[[@b7-crt-2015-171]\] emphasized the low possibility of curative resection with data showing 62% R0 resection. In the study by Neuhaus et al. \[[@b8-crt-2015-171]\], R0-1 resection was achieved in approximately 37% of the patients and was the only factor showing significant correlation with the DSS. In addition, adjuvant RT for RIS should be administered with caution because of the higher risk of RT-related toxicities.

RT plays a critical role in the treatment of most cancers. Therefore, concerns about RIS are emerging among cancer survivors because the survival rate and the survival time after cancer treatment are increasing as a result of advanced treatments including the use of targeted agents.

Most studies of RIS in Asia are case reports, and significantly under-reported compared to western countries. RIS patients tend to be referred to a large tertiary center because of the surgical complexity, therefore we report herein the incidence and experience in management of RIS at a single large tertiary referral center for 15 years.

Materials and Methods
=====================

After receiving institutional review board approval, we retrospectively reviewed our institutional sarcoma registry from January 2000 to April 2014. Out of the 3,674 patients in the registry, we identified 33 patients who met the following criteria for RIS, which were modifications of Cahan's criteria: (1) pathologic confirmation of sarcoma that was histologically unique from the primary cancer, (2) occurrence of the sarcoma in the field of radiation, and (3) radiation exposure at least 6 months before development of the sarcoma \[[@b9-crt-2015-171]\].

Medical records were reviewed for the patients' age, sex, primary cancer treatment, RIS characteristics, RIS treatment, and follow-up data. The radiographic image of RIS and the histopathology report were assessed for identification of the tumor location, size, and histology. All available medical records from the follow-up were reviewed for evaluation of the disease status and toxicity. The toxicities from re-irradiation were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0.

1. Statistical analysis
-----------------------

The overall survival rate was calculated from the time of the RIS diagnosis until death. Actuarial survival curves were plotted from the RIS diagnosis using the Kaplan-Meier method. A p-value less than 0.05 was considered to indicate a statistically significant difference. Analyses were performed using PASW ver. 18.0 (SPSS Inc., Chicago, IL).

Results
=======

1. Patients and tumor characteristics
-------------------------------------

A total of 33 patients diagnosed with RIS were identified. The number of cases increased from four cases in the years 2000-2003 to 14 cases in the years 2012-2014 with corresponding proportion of RIS among sarcoma patients of 0.5% to 1.6% ([Fig. 1](#f1-crt-2015-171){ref-type="fig"}).

A list of the characteristics of the 33 patients is shown in [Table 1](#t1-crt-2015-171){ref-type="table"}. Females accounted for 75.8% of the patients. The median age at the primary radiotherapy was 44 years (range, 0 to 71 years). Three patients were treated before age 20 (for bilateral retinoblastoma, Wilms' tumor, and nasopharyngeal cancer), and 20 patients were treated in their 40s and 50s. The median age at the RIS diagnosis was 55 years (range, 22 to 85 years), and the median latency was 12.1 years (range, 1.9 to 28.8 years).

The most common type of primary cancer was breast cancer (n=9), followed by uterine cervical cancer (n=8), and head and neck cancer (n=7). The median prescribed dose for primary RT was 50.4 Gy. All patients received a dose greater than 45 Gy, with the exception of three patients with Wilms' tumor, retinoblastoma, and lymphoma treated with 10.8 Gy, 36 Gy, and 30 Gy, respectively. Four patients underwent intracavitary brachytherapy in addition to external-beam RT for treatment of cervical cancer; 58% of patients underwent chemotherapy as their primary cancer treatment.

RIS was located in the trunk in 75.8% of the cases, and in the head and neck in 24.2%. The most common histology was osteosarcoma (36.4%), followed by malignant fibrous histiocytoma (33.3%) and angiosarcoma (6.1%). The median tumor size was 4.8 cm (range, 1.5 to 12.5 cm), and tumors were located deep in the muscle fascia in 27 cases (81.8%).

2. Treatment of RIS and outcome
-------------------------------

The median follow-up period was 23.1 months (range, 2.2 to 174.8 months). Nineteen patients underwent surgery with curative intent, while 14 patients were treated conservatively. A list of the details of the treatment of 19 patients with curative surgery is shown in [Table 2](#t2-crt-2015-171){ref-type="table"}. R0 resection was achieved, except in one patient. Four patients underwent neo-adjuvant chemotherapy, and six patients, adjuvant chemotherapy. One patient diagnosed with malignant histiocytoma in the mandible underwent adjuvant RT. The median overall survival period of all patients was 2.9 years, and their 5-year survival rate was 44.7%. In univariate and multivariate analyses, the age at diagnosis and the treatment aim showed association with the overall survival ([Table 3](#t3-crt-2015-171){ref-type="table"}). The median duration of the overall survival period and the 5-year survival rate of patients treated with curative surgery were 9.6 years and 65%, respectively, and that of the conservatively treated patients, 0.7 years and 0% (p=0.001) ([Fig. 2](#f2-crt-2015-171){ref-type="fig"}).

The treatment outcomes are summarized in [Fig. 3](#f3-crt-2015-171){ref-type="fig"}. Out of the 19 patients treated with curative resection, local recurrence occurred in nine patients (47%), and distant metastasis, in seven patients (37%).

3. Re-irradiation and toxicity
------------------------------

Nine patients underwent re-irradiation for various intents. Four patients were misdiagnosed with bone metastasis from their primary tumor and underwent palliative RT before biopsy. Three patients underwent palliative radiotherapy, one patient was treated with gamma knife surgery of the recurred mass, and one patient underwent adjuvant RT after curative surgery. Five patients, including the familial retinoblastoma patient who developed grade 4 skin necrosis after re-irradiation, showed radiation toxicity after re-irradiation ([Table 4](#t4-crt-2015-171){ref-type="table"}).

Discussion
==========

To the best of our knowledge, this is the first study reporting on the incidence and survival of RIS in Asia in a significant number of patients. Our data showed that, although rare, the number of patients diagnosed with RIS in our institution is consistently increasing with time. This may be due to the significant increase of RT usage in cancer therapy in South Korea since the first Cobalt-60 teletherapy installation in 1963. Patients undergoing RT increased from 22,000 in 1999 to 52,000 in 2011 \[[@b10-crt-2015-171]\]. The increased survival time of cancer patients could also be attributed to the increasing incidence of RIS.

RIS is known to have a worse prognosis than sporadic STS. Bjerkehagen et al. \[[@b5-crt-2015-171]\] investigated the question of whether or not a previous RT history is a worse prognosticator. In their analysis, a previous RT history was not a prognostic factor, but unlike sporadic STS, RIS tended to occur in a central location and to be associated with incomplete surgery, which are known poor prognosticators in sarcoma. As Cha et al. \[[@b11-crt-2015-171]\] stated, previous RT might obscure the anatomic and tumor planes, which might make radical resection challenging. Consistently in our data, only 57.6% of the patients could be treated with curative intent, and the survival outcome differed significantly according to the treatment aim.

In addition, the adjuvant RT for RIS is limited by the concern for possible complications regarding re-irradiation, which can hinder optimal RIS management. An adjuvant RT of 42-63 Gy is known to reduce local recurrence of STS after conservative surgery \[[@b12-crt-2015-171],[@b13-crt-2015-171]\]. However, as shown in this study, RT for RIS results in a high rate of RT-related complications, which is inevitable in high-dose regions. Due to the rarity and the histologic diversity within RIS, it is difficult to analyze the efficacy of secondary adjuvant RT after curative resection of RIS. Extrapolating from sporadic STS, adjuvant RT should also be performed for RIS, but care is required in the process of consultation with the patient, RT planning, and prescription of the RT dose. Also, high-precision RT techniques with increased conformality, such as intensity-modulated radiation therapy (IMRT), should be used in such re-irradiation cases to minimize the toxicity.

The question of whether or not the use of IMRT, stereotactic body radiation therapy, or proton therapy would reduce RIS incidence is yet to be determined. From the follow-up observation data on atomic bomb survivors who showed no excess of sarcoma after exposure to radiation of a few Gy, we acknowledge that RIS is less likely to arise in very low-dose regions, and more likely to arise in intermediate- to high-dose regions of above 5 Gy, with some evidence of a dose-response relationship \[[@b14-crt-2015-171],[@b15-crt-2015-171]\]. However, as studies regarding RIS, including this study, lack data on the initial dose prescribed for the RIS lesion due to the loss or incompleteness of the topographic primary RT planning information, accurate dose-incidence evaluation is limited. Increased conformality with high-precision RT techniques would reduce the high-dose region, but integral doses in irradiated regions can be increased. In this context, Hall and Wuu \[[@b16-crt-2015-171]\] insisted that IMRT would double the incidence of secondary malignancy. On the contrary, in a risk estimation study, IMRT or proton therapy did not increase the risk of secondary cancer, but it was assumed that proton therapy reduced the incidence \[[@b17-crt-2015-171]\]. These findings should be demonstrated by clinical data in future studies.

In this study, four RIS patients misdiagnosed with bone metastasis underwent palliative RT before the biopsy, which is not an optimal treatment for RIS. Although rare, the possibility of RIS must be considered when malignancy is suspected in the previously irradiated region, and pathologic confirmation must be considered before the treatment.

In this respect, identifying predisposing factors for development of RIS could be of clinical concern. In the US Surveillance, Epidemiology and End Results analysis by Berrington de Gonzalez et al. \[[@b14-crt-2015-171]\], a higher standardized incidence ratio for subsequent primary sarcoma was observed for patients treated at a younger age than those treated at older ages. In addition, several studies reported multiplicative effects of radiotherapy and chemotherapy for the subsequent risk of sarcoma \[[@b18-crt-2015-171]-[@b21-crt-2015-171]\]. However, there is a limitation in explaining the occurrence of RIS with these clinical factors giving way to the idea of possible genetic predisposition of a patient for development of RIS. Cha et al. \[[@b11-crt-2015-171]\] pointed out that in the early 2000s, there was no molecular or pathological marker that was helpful in accurately distinguishing RIS from spontaneous sarcoma, and little has changed since then. A study by Kacker et al. \[[@b22-crt-2015-171]\] found that *MYC* gene amplification was prevalent in RIS. On the other hand, the study by Kadouri et al. \[[@b1-crt-2015-171]\], investigating the role of p53 and *BRCA* mutation in RIS development, found a higher frequency of *BRCA* mutation in RIS patients, but was insignificant, thus they concluded that *BRCA* mutation should not be considered when making the treatment decision. An *in vivo* study by Kansara et al. \[[@b23-crt-2015-171]\] reported evidence that RB1 is required for development of radiation-induced osteosarcoma. A study by Hadj-Hamou et al. \[[@b24-crt-2015-171]\] comparing the transcriptome of sporadic sarcoma with that of RIS showed 135 gene signatures which could differentiate RIS from sporadic sarcoma, which indicated mitochondrial dysfunction with a hallmark of chronic oxidative stress. However, studies on genetic factors related to RIS are still in their early stage. Future studies on the biological background of RIS should be conducted in two major parts: that on the genetic susceptibility to RIS to distinguish high-risk patients before RT, and that on the molecular "radiation signature" that can distinguish RIS from sporadic STS beyond Cahan's criteria \[[@b9-crt-2015-171],[@b14-crt-2015-171]\].

Conclusion
==========

In this study, we found that 0.9% of the sarcoma patients in the registry of a large tertiary center met the RIS criteria. Although prognosis of RIS is poorer than that of sporadic STS, a surgical approach with curative intent is needed if possible, from which we can expect a favorable survival outcome, as seen in this study. Considering the aforementioned difficulties in RIS treatment, future study should focus on selection of RIS patient candidates using molecular markers before RT and should compare the risks and benefits of administering RT before the treatment. In addition, enhancing the precision of RT would contribute to the reduction of RIS or related complications in the future, but warrants further investigation.

Conflict of interest relevant to this article was not reported.

![Incidence of radiation induced sarcoma in a tertiary referral center in Korea. Numbers in parentheses denote the radiation-induced sarcoma (RIS) cases per all sarcoma patients in given periods](crt-2015-171f1){#f1-crt-2015-171}

![Overall survival of patients with radiation induced sarcoma.](crt-2015-171f2){#f2-crt-2015-171}

![Summary of treatment outcome of patients with radiation-induced sarcoma. NED, no evidence of disease.](crt-2015-171f3){#f3-crt-2015-171}

###### 

Characteristics of patients and radiation-induced sarcoma (RIS)

  Characteristic                                         No. (%)
  ------------------------------------------------------ -----------------
  **Sex**                                                
   Male                                                  8 (24.2)
   Female                                                25 (75.8)
  **Age at primary radiotherapy, median (range, yr)**    44 (0-71)
   0-19                                                  3 (9.1)
   20-39                                                 6 (18.2)
   40-59                                                 20 (60.6)
   ≥ 60                                                  4 (12.1)
  **Age at diagnosis of RIS, median (range, yr)**        55 (22-85)
  **Latency, median (range, yr)**                        12.1 (1.9-28.8)
  **Primary tumor**                                      
   Breast ca.                                            9 (27.3)
   Cervical ca.                                          8 (24.2)
   Rectal ca.                                            5 (15.2)
   Head and neck ca.                                     7 (21.2)
   Retinoblastoma                                        1 (3.0)
   Craniopharyngioma                                     1 (3.0)
   Lymphoma (DLBC, spine)                                1 (3.0)
   Wilms\' tumor                                         1 (3.0)
  **Radiation dose (Gy)**                                
   \< 20                                                 1 (3.0)
   20-40                                                 2 (6.0)
   40-60                                                 17 (51.5)
   ≥ 60[^a)^](#tfn2-crt-2015-171){ref-type="table-fn"}   13 (39.4)
  **Chemotherapy for primary cancer**                    
   Yes                                                   21 (63.3)
   No                                                    12 (36.7)
  **RIS location**                                       
   Trunk                                                 25 (75.8)
   Head and neck                                         8 (24.2)
  **RIS histology**                                      
   Osteosarcoma                                          12 (36.4)
   MFH                                                   11 (33.3)
   Angiosarcoma                                          2 (6.1)
   Chondrosarcoma                                        1 (3.0)
   Endometrial stromal sarcoma                           1 (3.0)
   Low-grade fibromyxoid sarcoma                         1 (3.0)
   Myxofibrosarcoma                                      1 (3.0)
   Myxoid liposarcoma                                    1 (3.0)
   Undifferentiated sarcoma                              1 (3.0)
   Sarcoma unspecified                                   1 (3.0)
  **Tumor size, median (range, cm)**                     4.8 (1.5-12.5)
  **Tumor depth**                                        
   Deep                                                  27 (81.8)
   Superficial                                           6 (18.2)

RIS, radiation induced sarcoma; DLBC, diffuse large B cell; MFH, malignant histiocytoma.

Four patients received intracavitary brachytherapy in addition to external-beam radiation therapy for treatment of cervical cancer.

###### 

Patients treated with curative intent for radiation-induced sarcoma (RIS)

  No.   Sex   Age at primary RT (yr)   Primary tumor            Duration to RIS (yr)   RIS histology         Initial RT dose (cGy)   RIS treatment   RM   Disease status                      Survival status at last follow-up
  ----- ----- ------------------------ ------------------------ ---------------------- --------------------- ----------------------- --------------- ---- ----------------------------------- -----------------------------------
  1     F     34                       Breast ca.               9.7                    OSA                   6,040                   RT+CTx+Op+CTx   R0   NED with 10 yr survival             Death
  2     F     44                       Breast ca.               5.7                    Angiosarcoma          6,100                   Op+CTx          R0   LR after 10 mo                      Alive
  3     F     51                       Breast ca.               7.7                    Angiosarcoma          5,940                   〇p             R0   LR after 4 mo                       Death
  4     F     30                       Breast ca.               13.1                   OSA                   4,680                   Op              R1   LR after 6 mo                       Death
  5     F     40                       Breast ca.               8.2                    Chondrosarcoma        6,600                   Op              R0   LR after 3 mo and DM after 3 mo     Alive
  6     F     48                       Breast ca.               4.8                    MFH                   5,040                   Op              R0   LR after 13 mo and DM after 13 mo   Alive
  7     F     45                       Cervical ca.             26.9                   OSA                   5,040                   Op+CTx          R0   NED                                 Alive
  8     F     40                       Cervical ca.             14.9                   OSA                   5,040                   CTx+Op          R0   NED                                 Alive
  9     F     49                       Cervical ca.             13.2                   MFH                   6,040+ICR               RT+Op           R0   LR after 15 mo                      Alive
  10    F     52                       Cervical ca.             6.7                    Myxoid liposarcoma    5,040+ICR               〇p             R0   LR after 12 mo                      Alive
  11    F     44                       Cervical ca.             17.6                   MFH                   5,040                   CTx+Op          R0   DM after 15 mo                      Alive
  12    F     67                       Rectal ca.               8.4                    MFH                   5,400                   〇p             R0   NED with wound complication         Death
  13    M     55                       Rectal ca.               13.3                   OSA                   5,040                   Op+CTx          R0   DM after 10 mo                      Death
  14    M     37                       Rectal ca.               26                     MFH                   5,040                   Op              R0   LR after 21 mo and DM after 29 mo   Death
  15    M     17                       Nasopharynx ca.          14.6                   OSA                   7,020                   Op+CTx          R0   NED                                 Alive
  16    F     53                       Nasopharynx ca. (ACC)    10.2                   OSA                   6,000                   Op+CTx          R0   LR after 14 mo and DM after 24 mo   Alive
  17    F     41                       Craniopharyngioma        13.2                   MFH                   5,440                   CTx+Op          R0   NED with 10 yr survival             Death
  18    M     53                       Parotid ca. (ACC)        10.8                   MFH                   7,040                   Op+RT           R0   DM after 10 mo                      Alive
  19    F     50                       Lymphoma (DLBC, trunk)   1.9                    Fibromyxoid sarcoma   3,000                   〇p             R0   NED                                 Alive

RT, radiotherapy; RM, resection margin; F, female; ca., cancer; OSA, osteosarcoma; CTx, chemotherapy; Op, operation; NED, no evidence of disease; LR, local recurrence; DM, distant metastasis; MFH, malignant histiocytoma; ICR, intracavitary radiotherapy; M, male; ACC, adenoid cystic carcinoma; DLBC, diffuse large B cell.

###### 

Univariate and multivariate analyses for overall survival

  Characteristic                                 No.   Median survival (mo)   p-value[^a)^](#tfn5-crt-2015-171){ref-type="table-fn"} (univariate)   p-value[^b)^](#tfn6-crt-2015-171){ref-type="table-fn"} (multivariate)
  ---------------------------------------------- ----- ---------------------- --------------------------------------------------------------------- -----------------------------------------------------------------------
  **Sex**                                                                                                                                           
   Male                                          8     28.4                   0.601                                                                 0.204
   Female                                        25    23.1                                                                                         
  **Age at primary radiotherapy, median (yr)**                                                                                                      
   ≤ 44                                          17    34.9                   0.886                                                                 \-
   \> 44                                         16    23.1                                                                                         
  **Age at diagnosis of RIS, median (yr)**                                                                                                          
   ≤ 55                                          18    115.2                  0.218                                                                 0.010[^c)^](#tfn7-crt-2015-171){ref-type="table-fn"}
   \> 55                                         15    23.1                                                                                         
  **Latency, median**                                                                                                                               
   ≤ 12                                          16    115.2                  0.233                                                                 0.176
   \> 12                                         17    23.3                                                                                         
  **Chemotherapy for primary cancer**                                                                                                               
   Yes                                           21    34.9                   0.704                                                                 \-
   No                                            12    28.4                                                                                         
  **RIS location**                                                                                                                                  
   Trunk                                         25    34.9                   0.613                                                                 0.865
   Head and neck                                 8     14.8                                                                                         
  **RIS histology**                                                                                                                                 
   MFH                                           11    124.0                  0.121                                                                 0.376
   Osteosarcoma                                  12    23.3                                                                                         
   Others                                        10    14.8                                                                                         
  **Tumor size (cm)**                                                                                                                               
   ≤ 5                                           19    34.9                   0.858                                                                 0.284
   \> 5                                          14    23.3                                                                                         
  **Tumor depth**                                                                                                                                   
   Deep                                          27    22.2                   0.980                                                                 0.320
   Superficial                                   6     34.9                                                                                         
  **Treatment**                                                                                                                                     
   Curative                                      19    115.2                  0.001                                                                 0.001[^c)^](#tfn7-crt-2015-171){ref-type="table-fn"}
   Palliation                                    14    8.0                                                                                          

RIS, radiation induced sarcoma; MFH, malignant histiocytoma.

Log-rank test,

Cox regression analysis,

Statistically significant.

###### 

Characteristics and outcome of patients with re-irradiation

  No.   Sex   Age at primary RT (yr)   Duration to RIS (yr)   Primary cancer       Site           Initial RT dose (cGy)   Radiation for RIS      Dose             RT technique   Toxicity
  ----- ----- ------------------------ ---------------------- -------------------- -------------- ----------------------- ---------------------- ---------------- -------------- ------------------------------------------
  1     F     0                        28.8                   Retinoblastoma       Skull base     3,600                   Palliative RT          45 Gy/15Fx       3D             Gr 4 skin necrosis
  2     F     34                       9.7                    Breast ca.           Clavicle       6,040                   RT before diagnosis    39 Gy/3Fx        Cyberknife     Gr 3 wound complication, Gr 2 neuropathy
  3     M     47                       4.4                    Rectal ca.           Pelvis         5,000                   RT before diagnosis    50 Gy/25 Fx      IMRT           Gr 2 neuropathy
  4     F     53                       10.2                   Nasopharyngeal ca.   Skull base     6,000                   Salvage radiosurgery   8 Gy at 50% X3   GKS            Gr 2 cranial neuropathy
  5     M     53                       10.8                   Parotid ca.          Mandible       7,040                   Adjuvant RT            61.2 Gy/34 Fx    3D             Carotid artery stenosis
  6     F     48                       5.8                    Breast ca.           Chest wall     5,040                   RT before diagnosis    12.5Gy/5Fx       3D             \-
  7     F     57                       20.2                   Nasal cavity ca.     Nasal cavity   5,940                   Palliative RT          45 Gy/15 Fx      3D             \-
  8     F     41                       13.2                   Cervical ca.         Pelvis         6,040+ICR               RT before diagnosis    30 Gy/10 Fx      3D             \-
  9     F     3                        19.1                   Wilms' tumor         Pelvis         1,080                   Palliative RT          39 Gy/13 Fx      3D             \-

RT, radiotherapy; RIS, radiation-induced sarcoma; F, female; 3D, three-dimensional conformal radiation therapy; Gr, grade; ca., cancer; M, male; IMRT, intensity-modulated radiation therapy; GKS, gamma knife surgery; ICR, intracavitary radiotherapy.
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